Original Source(s)
Related Content
FDA Approves Treg Cell Therapy
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
July 1, 2026
-
2 min
FDA monthly preview: Key September decisions to watch
Several FDA decisions across multiple specialties are expected this month.
August 28, 2026
-
5 min
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min